Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.
about
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.Oral health-related complications of breast cancer treatment: assessing dental hygienists' knowledge and professional practice.Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissuesEfficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinomaEGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.The molecular genetics of breast cancer and targeted therapyTrastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.Evaluation of HER2 in breast cancer: reality and expectations.Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.Next generation sequencing: implications in personalized medicine and pharmacogenomics.Expression and Characterization of the Extracellular Domain of Human HER2 from Escherichia Coli, and Production of Polyclonal Antibodies Against the Recombinant Proteins.Oral Health-Related Complications of Breast Cancer Treatment: Assessing Dental Hygienists' Knowledge and Professional Practice.
P2860
Q33284158-5BB2DFED-E568-46E7-97DA-048A5D42AD3CQ33821112-B8266AFC-1716-461B-9E32-465A1A69F141Q34501712-38ED38F3-3E0C-4FB8-A0A7-F864472930E0Q35161280-913C3F91-9E5A-4C84-91F6-19EF701136D6Q37206247-31733200-A7FF-43A6-AC37-0F2D3833FE58Q37290512-9EA0CE84-F435-4270-9136-E4BE831E2B31Q37477060-1FB9ABAD-3704-4EC3-9615-30FF9FFD819DQ38089837-A788B99F-638C-4254-86BD-D38227903396Q38152742-F0C4A7BA-C0FA-430F-BA81-EDABFBA17AEBQ38804924-8A6073D7-8DB7-4817-8273-67172A89D156Q38883112-831C3630-E965-4B0B-ACA9-C7E031874AE9Q54936088-A34A4354-B407-459E-AF4C-A2D12767AA17
P2860
Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Adjuvant trastuzumab therapy f ...... d what we still need to learn.
@ast
Adjuvant trastuzumab therapy f ...... d what we still need to learn.
@en
type
label
Adjuvant trastuzumab therapy f ...... d what we still need to learn.
@ast
Adjuvant trastuzumab therapy f ...... d what we still need to learn.
@en
prefLabel
Adjuvant trastuzumab therapy f ...... d what we still need to learn.
@ast
Adjuvant trastuzumab therapy f ...... d what we still need to learn.
@en
P1476
Adjuvant trastuzumab therapy f ...... d what we still need to learn.
@en
P304
P356
10.1016/J.EJCA.2006.04.008
P577
2006-06-27T00:00:00Z